Principal Financial Group Inc. lessened its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 2.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 647,066 shares of the company’s stock after selling 13,737 shares during the period. Principal Financial Group Inc. owned approximately 1.73% of Omnicell worth $33,033,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of the business. Stevens Capital Management LP purchased a new stake in Omnicell during the third quarter valued at about $305,000. Kornitzer Capital Management Inc. KS grew its position in Omnicell by 20.8% during the third quarter. Kornitzer Capital Management Inc. KS now owns 155,240 shares of the company’s stock valued at $7,925,000 after acquiring an additional 26,700 shares during the period. Bridge City Capital LLC grew its position in Omnicell by 8.7% during the third quarter. Bridge City Capital LLC now owns 22,404 shares of the company’s stock valued at $1,144,000 after acquiring an additional 1,796 shares during the period. Conestoga Capital Advisors LLC grew its position in Omnicell by 0.7% during the third quarter. Conestoga Capital Advisors LLC now owns 1,617,706 shares of the company’s stock valued at $82,584,000 after acquiring an additional 11,105 shares during the period. Finally, Crossmark Global Holdings Inc. purchased a new stake in Omnicell during the third quarter valued at about $596,000. 98.64% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts have issued reports on OMCL shares. Dougherty & Co boosted their price target on Omnicell from $45.00 to $49.00 and gave the company a “buy” rating in a research report on Friday, July 28th. Craig Hallum upped their target price on Omnicell from $46.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, July 28th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $47.00 target price on shares of Omnicell in a research report on Tuesday, July 25th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $55.00 target price on shares of Omnicell in a research report on Thursday, October 19th. Finally, Benchmark Co. upped their target price on Omnicell from $55.00 to $67.00 and gave the stock a “buy” rating in a research report on Tuesday, September 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $54.86.
COPYRIGHT VIOLATION NOTICE: “Principal Financial Group Inc. Lowers Holdings in Omnicell, Inc. (OMCL)” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://sportsperspectives.com/2017/11/18/principal-financial-group-inc-lowers-holdings-in-omnicell-inc-omcl.html.
Shares of Omnicell, Inc. (NASDAQ:OMCL) opened at $48.25 on Friday. Omnicell, Inc. has a one year low of $31.85 and a one year high of $55.40. The company has a quick ratio of 1.08, a current ratio of 1.53 and a debt-to-equity ratio of 0.38.
Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, October 26th. The company reported $0.42 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.42. Omnicell had a negative return on equity of 0.79% and a negative net margin of 0.51%. The firm had revenue of $186.78 million for the quarter, compared to analysts’ expectations of $192.45 million. During the same quarter in the prior year, the firm posted $0.40 earnings per share. Omnicell’s revenue for the quarter was up 5.7% compared to the same quarter last year. analysts predict that Omnicell, Inc. will post 0.12 earnings per share for the current year.
In other news, EVP Dan S. Johnston sold 14,613 shares of the stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $47.81, for a total transaction of $698,647.53. Following the sale, the executive vice president now directly owns 43,621 shares in the company, valued at approximately $2,085,520.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Randall A. Lipps sold 10,625 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $52.00, for a total value of $552,500.00. The disclosure for this sale can be found here. Insiders have sold a total of 50,569 shares of company stock worth $2,493,822 over the last quarter. Insiders own 3.77% of the company’s stock.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.